{"id":"placebo-to-denosumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Back pain"},{"rate":null,"effect":"Arthralgia"}]},"_chembl":{"chemblId":"CHEMBL1237023","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Denosumab blocks the interaction between RANKL and its receptor RANK on osteoclast precursor cells, thereby preventing osteoclast maturation and bone resorption. This leads to increased bone mineral density and reduced fracture risk in conditions characterized by excessive bone loss. Unlike bisphosphonates, denosumab does not require renal function for efficacy and acts through a targeted biological mechanism rather than direct effects on bone mineralization.","oneSentence":"Denosumab is a monoclonal antibody that binds to RANKL (receptor activator of nuclear factor kappa-B ligand) and prevents bone resorption by inhibiting osteoclast formation and activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:25.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postmenopausal osteoporosis in women at high risk of fracture"},{"name":"Bone loss in men receiving androgen deprivation therapy for prostate cancer"},{"name":"Bone loss in women receiving aromatase inhibitor therapy for breast cancer"},{"name":"Giant cell tumor of bone"},{"name":"Prevention of skeletal-related events in patients with bone metastases from solid tumors"}]},"trialDetails":[{"nctId":"NCT04608630","phase":"PHASE2","title":"Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults","status":"RECRUITING","sponsor":"Australian and New Zealand Intensive Care Research Centre","startDate":"2021-07-15","conditions":"Critical Illness, Osteoporosis","enrollment":450},{"nctId":"NCT06118905","phase":"PHASE4","title":"Preserving Geriatric Muscle With an Osteoporosis Medication","status":"RECRUITING","sponsor":"Susan L. Greenspan","startDate":"2024-02-08","conditions":"Osteoporosis","enrollment":155},{"nctId":"NCT04087096","phase":"PHASE4","title":"Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-08-24","conditions":"Bariatric Surgery Candidate, Bone Loss","enrollment":36},{"nctId":"NCT04067726","phase":"PHASE2","title":"RANKL Inhibition and Mammographic Breast Density","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2019-08-27","conditions":"Dense Breasts","enrollment":210},{"nctId":"NCT05655013","phase":"PHASE4","title":"Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2023-05-10","conditions":"Osteoporosis, Postmenopausal","enrollment":200},{"nctId":"NCT06524960","phase":"PHASE1, PHASE2","title":"Denosumab for Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-09-03","conditions":"Type 1 Diabetes","enrollment":45},{"nctId":"NCT07056478","phase":"PHASE3","title":"RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients","status":"NOT_YET_RECRUITING","sponsor":"Prince of Wales Hospital, Shatin, Hong Kong","startDate":"2026-01-01","conditions":"Sarcopenia in Elderly","enrollment":130},{"nctId":"NCT04711109","phase":"PHASE3","title":"Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-02-14","conditions":"BRCA1 Mutation, Breast Cancer, Breast Diseases","enrollment":300},{"nctId":"NCT04232657","phase":"PHASE2","title":"Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-03-01","conditions":"Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI","enrollment":36},{"nctId":"NCT03792763","phase":"PHASE2","title":"Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2019-09-30","conditions":"Multiple Myeloma","enrollment":8},{"nctId":"NCT06643780","phase":"PHASE4","title":"RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis","status":"RECRUITING","sponsor":"Prince of Wales Hospital, Shatin, Hong Kong","startDate":"2024-04-09","conditions":"Sarcopenia in Elderly","enrollment":120},{"nctId":"NCT02771860","phase":"PHASE2","title":"RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2016-03","conditions":"Hand Osteoarthritis","enrollment":100},{"nctId":"NCT01575834","phase":"PHASE3","title":"Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-15","conditions":"Postmenopausal Osteoporosis","enrollment":7180},{"nctId":"NCT06154707","phase":"PHASE3","title":"Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-02-01","conditions":"Sarcopenia, Osteoporosis, Denosumab","enrollment":86},{"nctId":"NCT03164928","phase":"PHASE3","title":"Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-05-07","conditions":"Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis","enrollment":24},{"nctId":"NCT03401060","phase":"PHASE3","title":"Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-03-05","conditions":"Osteoporosis, Systemic Mastocytosis","enrollment":24},{"nctId":"NCT03029442","phase":"PHASE4","title":"The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury","status":"TERMINATED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2017-04-01","conditions":"Secondary Osteoporosis, Spinal Cord Injury","enrollment":5},{"nctId":"NCT02864784","phase":"PHASE1","title":"Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC","status":"WITHDRAWN","sponsor":"Amorphical Ltd.","startDate":"2022-06","conditions":"Castrate Resistant Prostate Cancer With Bone Metastasis","enrollment":""},{"nctId":"NCT06272227","phase":"PHASE4","title":"Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2024-02-13","conditions":"Sarcopenia","enrollment":340},{"nctId":"NCT00556374","phase":"PHASE3","title":"Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12-18","conditions":"Breast Cancer","enrollment":3420},{"nctId":"NCT01345019","phase":"PHASE3","title":"Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-05-17","conditions":"Cancer, Hematologic Malignancies, Multiple Myeloma","enrollment":1718},{"nctId":"NCT00089791","phase":"PHASE3","title":"A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08-01","conditions":"Osteoporosis","enrollment":7808},{"nctId":"NCT00321464","phase":"PHASE3","title":"A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04-01","conditions":"Bone Metastases","enrollment":2049},{"nctId":"NCT00330759","phase":"PHASE3","title":"Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-01","conditions":"Bone Metastases","enrollment":1779},{"nctId":"NCT01558115","phase":"PHASE4","title":"Denosumab in Primary Hyperparathyroidism","status":"TERMINATED","sponsor":"Columbia University","startDate":"2012-01","conditions":"Primary Hyperparathyroidism","enrollment":8},{"nctId":"NCT00896532","phase":"PHASE2","title":"Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-06-03","conditions":"Low Bone Mineral Density, Postmenopausal Osteoporosis","enrollment":419},{"nctId":"NCT05278338","phase":"PHASE2","title":"Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2022-04-21","conditions":"Postmenopausal Osteoporosis","enrollment":200},{"nctId":"NCT03520231","phase":"PHASE2","title":"Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2018-09-04","conditions":"Urothelial Carcinoma, Kidney Cancer, Ureter Cancer","enrollment":6},{"nctId":"NCT01951586","phase":"PHASE2","title":"Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-12-31","conditions":"Non-Small Cell Lung Cancer","enrollment":226},{"nctId":"NCT00095498","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08-11","conditions":"Rheumatoid Arthritis","enrollment":227},{"nctId":"NCT02132026","phase":"PHASE2","title":"Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-11-12","conditions":"Calcific Aortic Stenosis","enrollment":152},{"nctId":"NCT01077154","phase":"PHASE3","title":"Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)","status":"TERMINATED","sponsor":"Amgen","startDate":"2010-06-02","conditions":"Breast Cancer","enrollment":4509},{"nctId":"NCT04231682","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.","status":"WITHDRAWN","sponsor":"Albert Einstein Healthcare Network","startDate":"2020-07-01","conditions":"Osteoporosis","enrollment":""},{"nctId":"NCT01732770","phase":"PHASE4","title":"Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-11-07","conditions":"Post Menopausal Osteoporosis","enrollment":643},{"nctId":"NCT01973569","phase":"NA","title":"AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2013-10","conditions":"Rheumatoid Arthritis","enrollment":679},{"nctId":"NCT02559648","phase":"PHASE2","title":"Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis","status":"COMPLETED","sponsor":"Ersi Voskaridou","startDate":"2014-09","conditions":"Thalassemia Major, Osteoporosis","enrollment":63},{"nctId":"NCT03822078","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-09-30","conditions":"Osteoporosis","enrollment":45},{"nctId":"NCT01983475","phase":"PHASE4","title":"Denosumab Administration After Spinal Cord Injury","status":"UNKNOWN","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2015-01","conditions":"Osteoporosis, Spinal Cord Injury","enrollment":24},{"nctId":"NCT02299817","phase":"PHASE2","title":"Denosumab for Treating Periprosthetic Osteolysis.","status":"UNKNOWN","sponsor":"Olof Skoldenberg","startDate":"2015-08","conditions":"Osteolysis","enrollment":20},{"nctId":"NCT00089661","phase":"PHASE3","title":"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-10-01","conditions":"Breast Cancer, Low Bone Mineral Density, Osteopenia","enrollment":252},{"nctId":"NCT00980174","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-10-01","conditions":"Low Bone Mass, Low Bone Mineral Density, Males With Osteoporosis","enrollment":242},{"nctId":"NCT00089674","phase":"PHASE3","title":"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08-01","conditions":"Prostate Cancer","enrollment":1468},{"nctId":"NCT00321620","phase":"PHASE3","title":"Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04-01","conditions":"Bone Metastases","enrollment":1904},{"nctId":"NCT01575873","phase":"PHASE3","title":"Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-28","conditions":"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor","enrollment":795},{"nctId":"NCT03427853","phase":"PHASE1","title":"A Study to Evaluate the Denosumab in Healthy Adults","status":"UNKNOWN","sponsor":"Luye Pharma Group Ltd.","startDate":"2018-01-10","conditions":"Healthy Adults","enrollment":32},{"nctId":"NCT00925600","phase":"PHASE3","title":"Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11-30","conditions":"Cancer, Cataract, Low Bone Mineral Density","enrollment":769},{"nctId":"NCT02135640","phase":"PHASE1","title":"China HVT Safety, PK, PD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-17","conditions":"Osteoporosis","enrollment":64},{"nctId":"NCT01920568","phase":"PHASE3","title":"A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08","conditions":"Fractures, Bone","enrollment":487},{"nctId":"NCT02014467","phase":"PHASE3","title":"Denosumab China Phase III Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01","conditions":"Osteoporosis, Postmenopausal","enrollment":486},{"nctId":"NCT00293813","phase":"PHASE2","title":"A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-05","conditions":"Postmenopausal Osteoporosis","enrollment":247},{"nctId":"NCT01457950","phase":"PHASE3","title":"A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11","conditions":"Osteoporosis, Postmenopausal","enrollment":135},{"nctId":"NCT00890981","phase":"PHASE3","title":"A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-07","conditions":"Low Bone Mass, Low Bone Mineral Density, Osteoporosis","enrollment":79},{"nctId":"NCT01495000","phase":"PHASE3","title":"A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01","conditions":"Osteoporosis, Postmenopausal","enrollment":250},{"nctId":"NCT00043186","phase":"PHASE2","title":"Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-05","conditions":"Low Bone Mineral Density","enrollment":412},{"nctId":"NCT00330460","phase":"PHASE3","title":"A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-05","conditions":"Osteoporosis, Osteopenia","enrollment":1189},{"nctId":"NCT00091793","phase":"PHASE3","title":"Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08","conditions":"Postmenopausal Osteoporosis","enrollment":332}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to Denosumab","genericName":"Placebo to Denosumab","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Denosumab is a monoclonal antibody that binds to RANKL (receptor activator of nuclear factor kappa-B ligand) and prevents bone resorption by inhibiting osteoclast formation and activation. Used for Postmenopausal osteoporosis in women at high risk of fracture, Bone loss in men receiving androgen deprivation therapy for prostate cancer, Bone loss in women receiving aromatase inhibitor therapy for breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}